Related Experiment Video
Updated: Jul 19, 2025
10:02
Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
Published on: June 10, 2022
2.2K
Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects
Edo Kon1,2,3,4, Nitay Ad-El1,2,3,4, Inbal Hazan-Halevy1,2,3,4
1Laboratory of Precision Nanomedicine, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Nature Reviews. Clinical Oncology
|August 16, 2023
Summary
Messenger RNA-lipid nanoparticles (mRNA-LNPs) show promise for cancer treatment, moving beyond COVID-19 vaccines. This review explores opportunities and challenges in using mRNA-LNP technology for oncology therapeutics and clinical translation.
Area of Science:
- Oncology
- Nanotechnology
- Immunotherapy
Background:
- Messenger RNA-lipid nanoparticles (mRNA-LNPs) have emerged as a versatile platform, initially recognized for their success in COVID-19 vaccines.
- Research is actively exploring mRNA-LNP applications in oncology, focusing on cancer vaccines and direct tumor treatments.
Purpose of the Study:
- To review the opportunities and challenges of utilizing mRNA-LNPs in oncology.
- To critically evaluate mRNA-LNP targeting and delivery strategies for cancer treatment.
- To identify obstacles hindering clinical translation of mRNA-LNP-based oncology therapeutics.
Main Methods:
- Review of preclinical and clinical studies on mRNA-LNP applications in cancer.
- Appraisal of various mRNA-LNP targeting and delivery strategies.
- Analysis of physiological, technological, and manufacturing challenges.
Main Results:
- mRNA-LNPs offer significant potential for cancer vaccines and direct intratumoral therapies.
- Various targeting and delivery strategies are being investigated for enhanced efficacy.
- Key challenges include physiological barriers, technological limitations, and manufacturing complexities.
Conclusions:
- mRNA-LNPs represent a promising frontier in oncology treatment.
- Addressing current obstacles is crucial for successful clinical translation of mRNA-LNP therapies.
- Further research and development are needed to fully realize the potential of mRNA-LNPs in cancer care.
